Shots:
- The P-III COV-BARRIER study evaluating Baricitinib (4 mg, qd) + SoC (corticosteroids, antimalarials, antivirals, azithromycin) vs PBO + SoC in 1525 patients hospitalized with COVID-19. The patients treated with baricitinib in addition to SoC includes 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both
- The trial did not meet 1EPs i.e. showed a 38% reduction in mortality by Day 28, non-invasive mechanical ventilation at baseline (17.5% vs 29.4%)
- Lilly plans to publish the data in a peer-reviewed journal in the coming mos. and share the data with regulatory authorities in the US, EU, and other geographies
Click here to read full press release/ article | Ref: Incyte | Image: Wikipedia
The post Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Hospitalized Patients with COVID-19 first appeared on PharmaShots.
